November 16, 2019, 5:30 – 6:45pm | Philadelphia Convention Center, Theater 1
Moving New Diagnostics into the Clinic in the 21st Century
Please join us for this exploration of the reasons traditional biomarkers are insufficient and why we must work across boundaries, old assumptions, and disciplines to reimagine the future in order to prevent, detect, and treat coronary heart disease.
- Dr. Calum MacRae, Lead, One Brave Idea
- Dr. Marc S. Penn, Co-Founder and Chief Medical Officer, Cleveland Heart Lab, Quest Diagnostics
- Dr. Paul Ridker, Director of the Center for Cardiovascular Disease Prevention and the Eugene Braunwald Professor of Medicine, Brigham and Women’s Hospital
- Dr. Naeem Khan, Vice President US Medical Affairs, Cardiovascular and Metabolic Diseases, AstraZeneca
- Dr. Rahul Deo, Chief Data Scientist, One Brave Idea
Who should attend:
Those who are interested in the intersections of academia, industry, and medicine and those who are excited about the applications of phenotypes and genotypes to advance biopharmacological discovery and clinical care should attend as well as those who are interested in learning more about the work of One Brave Idea.
For more information, please contact Diane Pickles, Program Director, One Brave Idea: email@example.com
Please note: This event is not part of the official Scientific Sessions 2019 as planned by the AHA Committee on Scientific Sessions Program.